Doc Go Inc. DCGO
We take great care to ensure that the data presented and summarized in this overview for DocGo Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding DCGO
View all-
Black Rock Inc. New York, NY6.21MShares$18.9 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY5.1MShares$15.6 Million0.43% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.86MShares$14.8 Million0.0% of portfolio
-
Wcm Investment Management, LLC Laguna Beach, CA2.63MShares$8.01 Million0.03% of portfolio
-
State Street Corp Boston, MA2.1MShares$6.4 Million0.0% of portfolio
-
S Squared Technology, LLC New York, NY1.94MShares$5.92 Million3.6% of portfolio
-
Knott David M Jr Syosset, NY1.93MShares$5.87 Million2.75% of portfolio
-
Geode Capital Management, LLC Boston, MA1.85MShares$5.65 Million0.0% of portfolio
-
Punch & Associates Investment Management, Inc. Edina, MN1.66MShares$5.06 Million0.4% of portfolio
-
P.A.W. Capital Corp1.5MShares$4.58 Million13.59% of portfolio
Latest Institutional Activity in DCGO
Top Purchases
Top Sells
About DCGO
DocGo, Inc. provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services. It also offers mobile health services through its platform that are performed at home and offices; COVID-19 testing; and event services, which include on-site healthcare support at sporting events and concerts. DocGo, Inc. was incorporated in 2015 and is headquartered in New York, New York.
Insider Transactions at DCGO
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 14
2024
|
Michael J Burdiek Director |
BUY
Open market or private purchase
|
Direct |
10,000
+1.69%
|
$30,000
$3.4 P/Share
|
May 13
2024
|
Lee Bienstock Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
25,000
+2.01%
|
$75,000
$3.15 P/Share
|
May 13
2024
|
Ely D Tendler General Counsel and Secretary |
BUY
Open market or private purchase
|
Direct |
10,000
+5.78%
|
$30,000
$3.13 P/Share
|
Mar 19
2024
|
Lee Bienstock Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,747
-0.31%
|
$18,735
$5.59 P/Share
|
Mar 15
2024
|
Stephen Sugrue Chief Compliance Officer |
BUY
Grant, award, or other acquisition
|
Direct |
68,306
+25.7%
|
-
|
Mar 15
2024
|
Steven Katz Director |
BUY
Open market or private purchase
|
Direct |
13,500
+16.26%
|
$40,500
$3.64 P/Share
|
Mar 15
2024
|
Lee Bienstock Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
218,579
+15.41%
|
-
|
Mar 15
2024
|
Norman Rosenberg CFO and Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
133,197
+24.64%
|
-
|
Mar 15
2024
|
Stanley Vashovsky Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,721
+0.28%
|
-
|
Mar 14
2024
|
Norman Rosenberg CFO and Treasurer |
BUY
Open market or private purchase
|
Direct |
10,000
+3.52%
|
$30,000
$3.61 P/Share
|
Mar 14
2024
|
Michael J Burdiek Director |
BUY
Open market or private purchase
|
Direct |
10,000
+1.72%
|
$30,000
$3.61 P/Share
|
Dec 15
2023
|
James M Travers Director |
BUY
Exercise of conversion of derivative security
|
Direct |
23,088
+29.18%
|
-
|
Dec 15
2023
|
Michael J Burdiek Director |
BUY
Exercise of conversion of derivative security
|
Direct |
23,088
+3.95%
|
-
|
Dec 12
2023
|
James M Travers Director |
BUY
Grant, award, or other acquisition
|
Direct |
32,946
+50.0%
|
-
|
Dec 12
2023
|
Ira Smedra Director |
BUY
Grant, award, or other acquisition
|
Direct |
32,946
+37.03%
|
-
|
Dec 12
2023
|
Michael J Burdiek Director |
BUY
Grant, award, or other acquisition
|
Direct |
32,946
+5.77%
|
-
|
Dec 12
2023
|
Etalvina Leite Director |
BUY
Grant, award, or other acquisition
|
Direct |
32,946
+50.0%
|
-
|
Dec 12
2023
|
Stanley Vashovsky Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,407
+0.2%
|
-
|
Dec 12
2023
|
Stephen Sugrue Chief Compliance Officer |
BUY
Grant, award, or other acquisition
|
Direct |
96,899
+42.87%
|
-
|
Dec 12
2023
|
Ely D Tendler General Counsel and Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
129,845
+31.2%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 1.77M shares |
---|---|
Exercise of conversion of derivative security | 76.2K shares |
Open market or private purchase | 78.5K shares |
Open market or private sale | 270K shares |
---|---|
Payment of exercise price or tax liability | 5.36K shares |
Bona fide gift | 1.2M shares |